We combined integrated claims with diagnosis codes and UM data to uncover indication-specific drug costs. Treating autoimmune conditions consumes more than $1 in $5 of…
These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA…
Blue Cross and Blue Shield of Kansas (BCBSKS) began preparing for gene therapy requests back in 2017, when Luxturna® (voretigene neparvovec-rzyl) was approved. At the time,…
